Pyxis Oncology, Inc. (PYXS)Healthcare | Biotechnology | Boston, United States | NasdaqGS
3.23 USD
-0.09
(-2.711%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 3.23 0.00 (0.000%) ⇩ (Aug. 28, 2026, 7:30 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 3:48 a.m. EDT
The investment case here is severely compromised by a brutal multi-year performance track record. Despite a brief rally in 2024, the company has suffered a catastrophic 63% drop in the most recent year, resulting in a nearly 49% cumulative loss over the last three years. This is not a temporary setback; it is a structural decline where the market has repeatedly punished the business, leaving it with negative earnings, negative free cash flow, and a return on equity that is deeply negative. The balance sheet is fragile, with debt-to-equity exceeding 155%, and the company is burning cash rapidly. While analysts project significant upside based on potential clinical success, the current reality is a distressed biotech with no dividend support and a history of failing to sustain value. The options market confirms this fear, with traders aggressively buying puts to hedge against further deterioration. There is no margin of safety here; the price reflects a business that has recently failed to deliver on its promises. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.172163 |
| AutoETS | 0.203889 |
| AutoARIMA | 0.245491 |
| AutoTheta | 0.255623 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 28% |
| H-stat | 3.61 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.944 |
| Excess Kurtosis | -0.12 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 155.874 |
| Revenue per Share | 0.175 |
| Market Cap | 269,408,000 |
| Forward P/E | -2.86 |
| Beta | 1.32 |
| Website | https://www.pyxisoncology.com |
As of Aug. 22, 2026, 3:48 a.m. EDT: Speculators are heavily positioned for downside protection, with October put open interest significantly outweighing call open interest at key strikes. While there is notable call volume at the $5.0 strike suggesting a speculative hope for a recovery, the overwhelming majority of option positioning (both volume and open interest) is concentrated in out-of-the-money puts, indicating a market consensus expecting further price weakness rather than an immediate bounce.
| Attribute | Value |
|---|---|
| 52 Week Change | 1.4285715 |
| Address1 | 321 Harrison Avenue |
| Address2 | 11th Floor, Suite 1 |
| All Time High | 19.0 |
| All Time Low | 0.833 |
| Ask | 3.25 |
| Ask Size | 1 |
| Average Analyst Rating | 1.3 - Strong Buy |
| Average Daily Volume10 Day | 584,900 |
| Average Daily Volume3 Month | 1,182,046 |
| Average Volume | 1,182,046 |
| Average Volume10Days | 584,900 |
| Beta | 1.318 |
| Bid | 3.24 |
| Bid Size | 1 |
| Book Value | 0.18 |
| City | Boston |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 3.23 |
| Current Ratio | 1.337 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 3.3796 |
| Day Low | 3.2001 |
| Debt To Equity | 155.874 |
| Display Name | Pyxis Oncology |
| Earnings Timestamp | 1,786,624,200 |
| Earnings Timestamp End | 1,793,622,600 |
| Earnings Timestamp Start | 1,793,622,600 |
| Ebitda | -85,526,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -2.973 |
| Enterprise To Revenue | 23.034 |
| Enterprise Value | 254,244,000 |
| Eps Current Year | -1.22 |
| Eps Forward | -1.12778 |
| Eps Trailing Twelve Months | -1.37 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 2.8156 |
| Fifty Day Average Change | 0.4144001 |
| Fifty Day Average Change Percent | 0.14718004 |
| Fifty Two Week Change Percent | 142.85715 |
| Fifty Two Week High | 5.55 |
| Fifty Two Week High Change | -2.3200002 |
| Fifty Two Week High Change Percent | -0.41801804 |
| Fifty Two Week Low | 1.03 |
| Fifty Two Week Low Change | 2.2 |
| Fifty Two Week Low Change Percent | 2.1359224 |
| Fifty Two Week Range | 1.03 - 5.55 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,633,699,800,000 |
| Float Shares | 49,561,063 |
| Forward Eps | -1.12778 |
| Forward P E | -2.864034 |
| Free Cashflow | -23,186,750 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 56 |
| Fullday Change | -0.0899999 |
| Fullday Change Percent | -2.71084 |
| Fullday Price | 3.2297 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.78366 |
| Gross Profits | 8,650,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.13525 |
| Held Percent Institutions | 0.425 |
| Implied Shares Outstanding | 83,408,050 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,021-10-08 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; PYX-102, an investigational immunotherapeutic targeting KLRG1, an inhibitory receptor on T cells and NK cells, with potential for use as monotherapy or in combination treatments; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients with several cancer indications, which is in Phase 2 clinical trial for the treatment of tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and pancreatic ductal adenocarcinoma. It has an in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates, including micvotabart pelidotin and PYX-203, and other ADC product candidates directed to the licensed targets; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts. |
| Long Name | Pyxis Oncology, Inc. |
| Market | us_market |
| Market Cap | 269,408,000 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_629268721 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -88,727,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 276,914,726 |
| Number Of Analyst Opinions | 9 |
| Open | 3.32 |
| Operating Cashflow | -67,910,000 |
| Operating Margins | -8.127379 |
| Payout Ratio | 0.0 |
| Phone | 617 453 3596 |
| Post Market Change | -0.00029993057 |
| Post Market Change Percent | -0.009285776 |
| Post Market Price | 3.2297 |
| Post Market Time | 1,787,959,806 |
| Previous Close | 3.32 |
| Price Eps Current Year | -2.647541 |
| Price Hint | 4 |
| Price To Book | 17.944445 |
| Price To Sales Trailing12 Months | 24.40732 |
| Profit Margins | 0.0 |
| Quick Ratio | 1.201 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.3 |
| Region | US |
| Regular Market Change | -0.0899999 |
| Regular Market Change Percent | -2.71084 |
| Regular Market Day High | 3.3796 |
| Regular Market Day Low | 3.2 |
| Regular Market Day Range | 3.2 - 3.3796 |
| Regular Market Open | 3.32 |
| Regular Market Previous Close | 3.32 |
| Regular Market Price | 3.23 |
| Regular Market Time | 1,787,947,200 |
| Regular Market Volume | 211,989 |
| Return On Assets | -0.62950003 |
| Return On Equity | -1.79096 |
| Revenue Per Share | 0.175 |
| Sand P52 Week Change | 0.20204377 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 83,408,050 |
| Shares Percent Shares Out | 0.0531 |
| Shares Short | 4,425,542 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 3,253,653 |
| Short Name | Pyxis Oncology, Inc. |
| Short Percent Of Float | 0.066199996 |
| Short Ratio | 2.95 |
| Source Interval | 15 |
| State | MA |
| Symbol | PYXS |
| Target High Price | 12.0 |
| Target Low Price | 5.0 |
| Target Mean Price | 7.22222 |
| Target Median Price | 7.0 |
| Total Cash | 32,996,000 |
| Total Cash Per Share | 0.396 |
| Total Debt | 17,832,000 |
| Total Revenue | 11,038,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.37 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 2.296375 |
| Two Hundred Day Average Change | 0.933625 |
| Two Hundred Day Average Change Percent | 0.40656468 |
| Type Disp | Equity |
| Volume | 211,989 |
| Website | https://www.pyxisoncology.com |
| Zip | 2,118 |